Eli
Gilboa, Ph.D., a national leader in translating promising
immune therapies from the laboratory into patient care—particularly
against cancer and HIV/AIDS—has joined the faculty
of the Miller School of Medicine. He will have dual appointments
in the Department of Microbiology and Immunology and
in the Division of Hematology Oncology at the University
of Miami Sylvester Comprehensive Cancer Center as he
develops an Interdisciplinary Immunotherapy Institute
that will serve patients across the Miller School. The
institute will focus on cancer, infectious diseases,
autoimmunity, and transplantation. In addition to yielding
therapies in each of those areas, the institute will
encourage synergism and cross-fertilization across disciplines.
Gilboa comes to Miami from Duke University,
where he has held dual appointments in the Departments
of Surgery and Immunology since 1993. He is a pioneer
in gene therapy, having developed the first generation
of retroviral vectors used in the first human trials.
He has continued to lead novel research into gene therapy
in oncology and HIV/ AIDS, and he has been an innovator
in RNA-based therapeutics. |